Jobaaj Stories
MHRA Issues Warning Over Lercanidipine 20mg Tablet Labelling Error
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has issued an alert regarding a labelling error on certain packs of Lercanidipine Hydrochloride 20mg tablets. This blood pressure medication is commonly prescribed to manage hypertension.
Details of the Labelling Error
The issue pertains to batch number MD4L07, which has an expiry date of January 2028. On some cartons of this batch, one side incorrectly states the strength as 10mg, while the actual tablets inside are 20mg. The correct strength is indicated on the blister foil packaging.
Guidance for Patients
If you are prescribed 10mg tablets:
-
Check the batch number on the blister foil.
-
If it reads MD4L07, consult your pharmacist or GP immediately.
-
If you cannot reach a healthcare professional before your next dose:
-
Confirm the tablet strength is 20mg as per the blister foil.
-
Break the tablet in half along the score line and take half.
-
This is a temporary measure until you can consult with your healthcare provider.
-
If you are prescribed 20mg tablets:
-
Verify the tablet strength by checking the blister foil.
-
Continue taking the medication as prescribed.
-
Do not stop taking your medicine without consulting your healthcare provider.
If you have taken a higher dose than prescribed or have concerns, speak to your pharmacist, GP, or call NHS 111.
Importance of Accurate Medication Labelling
Accurate labelling of medications is crucial to ensure patient safety and effective treatment. Incorrect labelling can lead to dosage errors, potentially causing adverse effects or reduced efficacy. Healthcare professionals and patients are urged to remain vigilant and report any discrepancies.
